Literature DB >> 31317370

Vanishing bile duct syndrome arising in a patient with HIV infection sequentially treated with trimethoprim/sulfamethoxazole and dapsone.

Pradeep Reddy Kathi1, Maher Tama2, Murray Ehrinpreis2, Milton Mutchnick2, Maria Westerhoff3, Jonathan Mowers3, Robert John Fontana4.   

Abstract

Trimethoprim/sulfamethoxazole is well known to cause intra-hepatic cholestasis which in rare instances can be prolonged and lead to vanishing bile duct syndrome. The risk regarding the potential for cross-reactivity between structurally related molecules such as dapsone and trimethoprim/sulfamethoxazole in causing hepatotoxicity is scarce. Herein, we report a case of vanishing bile duct syndrome following dapsone use in a patient with HIV infection and a recent history of trimethoprim/sulfamethoxazole-induced cholestasis. The patient had severe and protracted cholestasis during 2 years of follow-up and eventually died of liver failure.

Entities:  

Keywords:  Dapsone; Drug-induced liver injury; HIV; Trimethoprim sulfamethoxazole; Vanishing bile duct syndrome

Mesh:

Substances:

Year:  2019        PMID: 31317370     DOI: 10.1007/s12328-019-01022-5

Source DB:  PubMed          Journal:  Clin J Gastroenterol        ISSN: 1865-7265


  19 in total

1.  Dapsone is often tolerated in HIV-infected patients with history of sulfonamide antibiotic intolerance.

Authors:  Sara M May; Megan S Motosue; Miguel A Park
Journal:  J Allergy Clin Immunol Pract       Date:  2016-12-27

2.  Clinical presentations and outcomes of bile duct loss caused by drugs and herbal and dietary supplements.

Authors:  Herbert L Bonkovsky; David E Kleiner; Jiezhun Gu; Joseph A Odin; Mark W Russo; Victor M Navarro; Robert J Fontana; Marwan S Ghabril; Huiman Barnhart; Jay H Hoofnagle
Journal:  Hepatology       Date:  2017-02-07       Impact factor: 17.425

3.  Safety of dapsone as Pneumocystis carinii pneumonia prophylaxis in human immunodeficiency virus-infected patients with allergy to trimethoprim/sulfamethoxazole.

Authors:  M G Beumont; A Graziani; P A Ubel; R R MacGregor
Journal:  Am J Med       Date:  1996-06       Impact factor: 4.965

4.  Characteristics of idiosyncratic drug-induced liver injury in children: results from the DILIN prospective study.

Authors:  Jean P Molleston; Robert J Fontana; M James Lopez; David E Kleiner; Jiezhun Gu; Naga Chalasani
Journal:  J Pediatr Gastroenterol Nutr       Date:  2011-08       Impact factor: 2.839

5.  Trimethoprim-sulfamethoxazole-induced Stevens-Johnson syndrome: a case report.

Authors:  Michael R Langlois; Francis Derk; Ronald Belczyk; Thomas Zgonis
Journal:  J Am Podiatr Med Assoc       Date:  2010 Jul-Aug

6.  Severe and long lasting cholestasis after high-dose co-trimoxazole treatment for Pneumocystis pneumonia in HIV-infected patients--a report of two cases.

Authors:  F Hanses; S Zierhut; J Schölmerich; B Salzberger; C E Wrede
Journal:  Int J Infect Dis       Date:  2009-03-18       Impact factor: 3.623

7.  Successful orthotopic liver transplantation after trimethoprim-sulfamethoxazole associated fulminant liver failure.

Authors:  Fahim Zaman; Gang Ye; Kenneth D Abreo; Shahnila Latif; Gazi B Zibari
Journal:  Clin Transplant       Date:  2003-10       Impact factor: 2.863

8.  Cholestatic jaundice due to co-trimoxazole.

Authors:  A L Ogilvie; P J Toghill
Journal:  Postgrad Med J       Date:  1980-03       Impact factor: 2.401

Review 9.  Vanishing bile duct syndrome.

Authors:  Nancy S Reau; Donald M Jensen
Journal:  Clin Liver Dis       Date:  2008-02       Impact factor: 6.126

10.  Urosodeoxycholic Acid Therapy in a Child with Trimethoprim-Sulfamethoxazole-induced Vanishing Bile Duct Syndrome.

Authors:  Hyun Jeong Cho; Hye Jeong Jwa; Kyu Seon Kim; Dae Yong Gang; Jae Young Kim
Journal:  Pediatr Gastroenterol Hepatol Nutr       Date:  2013-12-31
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.